HAVCR2 and neoplasm: This heightened immune cell presence is consistent with the observed reduction in exhaustion markers, such as LAG-3, TIGIT, and TIM-3, emphasizing the potential of BJIKT and pembrolizumab to mitigate T cell exhaustion and sustain a robust anti-tumor immune response.